{
    "symbol": "CAPR",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-10 22:21:15",
    "content": " statements may include statements regarding, among other things, the efficacy, safety and intended utilization of our product candidates, our future R&D plans, including our anticipated conduct and timing of preclinical and clinical studies, our plans to present or report additional data, our plans regarding regulatory filings, potential regulatory developments involving our product candidates, potential milestone payments and our possible uses of existing cash and investment resources. We are hopeful that both the StealthX vaccine as well as the therapeutic exosome platform may provide opportunities for partnering, collaborative or business development, and we intend to make these potential alliances and increasing focus in our business development strategy alongside our efforts for possible partnerships for CAP-1002 in new territories."
}